SR-17018, sometimes written as SR17018 or SR-17, is an experimental research compound that acts on the mu-opioid receptor, the same broad receptor system involved with opioids such as morphine, oxycodone, heroin, and fentanyl. SR-17018 is not a prescription medication, and it is not approved by the FDA for treating pain, opioid withdrawal, opioid addiction, anxiety, …
SR-17018, sometimes written as SR17018 or SR-17, is an experimental research compound that acts on the mu-opioid receptor, the same broad receptor system involved with opioids such as morphine, oxycodone, heroin, and fentanyl.
SR-17018 is not a prescription medication, and it is not approved by the FDA for treating pain, opioid withdrawal, opioid addiction, anxiety, or any other medical condition. It is mainly discussed in scientific literature as a G protein-biased mu-opioid receptor agonist, meaning researchers are studying whether it activates opioid receptor signaling in a different way than traditional opioids.
Interest in SR-17018 comes from a larger effort to understand whether opioid-like compounds can provide pain relief with fewer risks, such as respiratory depression, tolerance, dependence, and addiction. However, “experimental” does not mean safe. Early research has raised important concerns about dependence, reward-related behavior, and withdrawal.
Why Are People Talking About SR-17018?
SR-17018 has gained attention because some preclinical studies suggest it may act differently from traditional opioids. In animal studies, researchers have investigated whether SR-17018 could produce pain-relieving effects while causing less tolerance or less respiratory depression than opioids like morphine or oxycodone.
That sounds promising on the surface, but the research is still early and mostly preclinical. SR-17018 is not an approved medication, and animal data cannot be treated as proof of safety in humans.
Some people online may discuss SR-17018 as a “safer opioid,” a potential opioid withdrawal tool, or a research chemical alternative to traditional opioids. That framing can be dangerous. Even if a compound behaves differently in a lab setting, it may still affect opioid receptors, still produce dependence, and still carry serious risks when used outside medical research.
SR-17018 and the Mu-Opioid Receptor
The mu-opioid receptor is one of the main targets for opioid drugs. When activated, this receptor can influence pain relief, reward, sedation, breathing, gastrointestinal function, mood, stress response, and physical dependence.
Traditional opioids activate mu-opioid receptors in ways that can produce both therapeutic and dangerous effects. These may include:
| Opioid Effect | Why It Matters |
|---|---|
| Pain relief | One reason opioids may be prescribed medically |
| Euphoria or emotional relief | Can reinforce misuse and repeated use |
| Sedation | Can impair judgment and increase overdose risk |
| Respiratory depression | Slowed breathing can become life-threatening |
| Constipation | A common opioid-related side effect |
| Tolerance | More of the drug may be needed over time |
| Dependence | Withdrawal symptoms can occur when stopping |
| Addiction risk | Continued use may become compulsive despite harm |
SR-17018 is being studied because it may activate some opioid receptor pathways more strongly than others. This is known as biased agonism. The hope behind this area of research is that certain opioid effects might one day be separated from others. However, current research does not prove that SR-17018 is safe for human use.
Is SR-17018 a Legal Medication?
No. SR-17018 is not an FDA-approved medication. It should not be viewed as a treatment for pain, opioid withdrawal, opioid use disorder, or any medical condition.
Because SR-17018 is a research compound, products sold online may have major safety concerns. These may include inaccurate labeling, unknown purity, inconsistent dosing, contamination, or misrepresentation. People who buy research chemicals online may not know what they are actually taking.
This is especially dangerous with opioid-like compounds because small differences in dose, potency, or purity can have serious consequences.
Can SR-17018 Cause Dependence or Withdrawal?
Current research suggests that SR-17018 may still carry dependence and withdrawal concerns. Some animal studies have found that SR-17018 can produce physical dependence and withdrawal-related symptoms after repeated exposure.
This matters because early online discussions sometimes imply that biased opioid compounds are automatically “non-addictive” or “withdrawal-free.” That is not what the research shows. Even if SR-17018 differs from morphine or oxycodone in certain ways, it still interacts with opioid receptor systems involved in dependence.
Possible opioid-like withdrawal symptoms may include:
| Symptom Category | Possible Symptoms |
| Physical symptoms | Sweating, chills, body aches, nausea, diarrhea, tremors |
| Sleep symptoms | Insomnia, restless sleep, vivid dreams |
| Mood symptoms | Anxiety, irritability, depression, agitation |
| Nervous system symptoms | Restlessness, racing heart, blood pressure changes |
| Cravings | Strong urges to take more of the substance |
| Functional symptoms | Difficulty working, sleeping, eating, or managing responsibilities |
Because SR-17018 is not an approved medication, there is no standardized human withdrawal timeline, no accepted detox protocol, and no clear medical dosing guidance for people using it outside research settings.
SR-17018 vs. Traditional Opioids
SR-17018 is often compared with traditional opioids because it acts at the mu-opioid receptor. However, it is important to separate research interest from real-world safety.
| Substance | Status | Main Receptor Concern | Key Risk |
| Morphine | Prescription opioid | Mu-opioid receptor agonist | Dependence, overdose, respiratory depression |
| Oxycodone | Prescription opioid | Mu-opioid receptor agonist | Misuse, addiction, overdose, withdrawal |
| Fentanyl | Prescription/synthetic illicit opioid | Potent mu-opioid receptor agonist | High overdose risk |
| Buprenorphine | FDA-approved medication for opioid use disorder and pain | Partial mu-opioid receptor agonist | Requires medical oversight |
| SR-17018 | Research compound | G protein-biased mu-opioid receptor agonist | Unknown human safety, dependence concerns, withdrawal risk |
The key difference is that medications like buprenorphine have approved clinical uses, established dosing guidance, and medical oversight. SR-17018 does not.
Is SR-17018 Being Studied for Opioid Withdrawal?
Some animal research has examined how SR-17018 interacts with morphine tolerance and withdrawal-related effects. Certain studies suggest SR-17018 may affect morphine withdrawal in animal models, but this does not mean SR-17018 is a safe or appropriate self-detox option.
There is a major difference between a controlled laboratory study and human use of an unapproved compound purchased online. Human withdrawal can be medically complex, especially when fentanyl, heroin, oxycodone, benzodiazepines, alcohol, gabapentin, kratom, xylazine, or other substances are involved.
Anyone struggling with opioid withdrawal should seek medical guidance rather than experimenting with research chemicals.
Why “Safer Opioid” Claims Can Be Misleading
The phrase “safer opioid” can create a false sense of security. In opioid research, a compound may appear safer in one specific measurement while still carrying other risks.
For example, a research compound might show less respiratory depression in one animal model but still raise concerns about:
| Concern | Why It Still Matters |
| Dependence | The body may adapt to repeated opioid receptor activation |
| Withdrawal | Stopping may cause physical and psychological symptoms |
| Reward | The compound may still reinforce repeated use |
| Unknown dosing | Human dosing may be unclear or unsafe |
| Product purity | Online research chemicals may be mislabeled or contaminated |
| Polysubstance risk | Mixing with alcohol, benzodiazepines, or opioids can increase harm |
| Lack of medical oversight | No approved treatment protocol exists for nonmedical use |
For people with a history of opioid addiction, even experimental opioid-like compounds can be risky. A substance does not need to be heroin or fentanyl to trigger cravings, relapse patterns, or withdrawal.
SR-17018 and Addiction Risk
Addiction is not only about a drug’s legal status or whether it is prescribed. Addiction can develop when a substance repeatedly activates brain systems involved in reward, relief, craving, and reinforcement.
A person may be at higher risk if they are using SR-17018 or similar research chemicals to:
| Pattern | Why It May Be Concerning |
| Avoid opioid withdrawal | May delay real treatment and prolong dependence |
| Replace heroin, fentanyl, or oxycodone | Can keep opioid receptor dependence active |
| Manage anxiety or emotional pain | May become a coping mechanism |
| Self-treat chronic pain | May lead to escalating use without medical oversight |
| Experiment with “legal” opioids | Legal status does not equal safety |
| Avoid detection | May increase secrecy and risky use patterns |
If someone feels unable to stop using SR-17018, opioids, kratom, or other substances without withdrawal or cravings, professional support may be appropriate.
What To Do If You Have Been Using SR-17018
If you have been using SR-17018, do not assume that stopping suddenly is risk-free. Because there is limited human data, it is difficult to predict what withdrawal may look like. Risk may be higher if SR-17018 has been used daily, in high amounts, or alongside other substances.
Consider seeking medical or clinical support if you experience:
| Warning Sign | Why It Matters |
| Withdrawal symptoms when stopping | May indicate physical dependence |
| Cravings or compulsive use | May signal addiction risk |
| Increasing dose over time | May reflect tolerance or loss of control |
| Mixing with opioids or sedatives | May increase overdose risk |
| Severe anxiety or insomnia | Can increase relapse risk |
| Confusion or heavy sedation | May require urgent medical evaluation |
| Suicidal thoughts | Requires immediate crisis support |
If someone is unconscious, breathing slowly, turning blue or gray, or cannot be woken up, call 911 immediately. If opioid overdose is possible, naloxone should be used while waiting for emergency help.
Treatment for Opioid and Research Chemical Use in Maine
At Portland Treatment, we support people struggling with opioid use, research chemical use, withdrawal concerns, and co-occurring mental health symptoms. Whether someone is using fentanyl, heroin, oxycodone, kratom, phenibut, or an experimental compound like SR-17018, the goal is to understand the full picture and build a safer path forward.
Treatment may include clinical assessment, medical referral when needed, relapse prevention planning, therapy, coping skills, and support for anxiety, depression, trauma, or polysubstance use. For people with opioid use disorder, evidence-based care may also include medication-assisted treatment coordination when appropriate.
Recovery is not about shame or judgment. It is about getting honest support before a risky pattern becomes more dangerous.
Frequently Asked Questions About SR-17018
What is SR-17018?
SR-17018 is an experimental research compound that acts on the mu-opioid receptor. It is being studied for its unusual opioid receptor signaling profile, but it is not an FDA-approved medication.
Is SR-17018 an opioid?
SR-17018 is generally described in research literature as a mu-opioid receptor agonist or opioid receptor modulator. It acts on the same broad receptor system involved with traditional opioids.
Is SR-17018 FDA-approved?
No. SR-17018 is not FDA-approved for pain, opioid withdrawal, opioid addiction, or any other medical use.
Can SR-17018 cause withdrawal?
Animal research suggests SR-17018 may produce physical dependence and withdrawal-related symptoms after repeated exposure. There is no standardized human withdrawal timeline because it is not an approved medication.
Is SR-17018 safer than fentanyl or oxycodone?
There is not enough human clinical evidence to call SR-17018 safe. It may behave differently from traditional opioids in certain studies, but that does not make it safe for nonmedical use.
Can SR-17018 treat opioid withdrawal?
SR-17018 should not be used as a self-directed opioid withdrawal treatment. Some animal studies have explored its relationship to morphine tolerance and withdrawal, but it is not an approved detox medication.
What should I do if I am using SR-17018 and want to stop?
Seek medical or clinical support, especially if you have been using it daily, using high amounts, or combining it with other substances. Because human data is limited, stopping suddenly may be unpredictable.
Sources
Cornelissen, J. C., Obeng, S., Rice, K. C., Banks, M. L., & Negus, S. S. (2021). Some effects of putative G-protein biased mu-opioid receptor agonists, including SR17018, in male rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8266741/
Fritzwanker, S., Mohr, K., Kliewer, A., et al. (2021). SR-17018 stimulates atypical μ-opioid receptor phosphorylation and dephosphorylation. Molecules, 26(15), 4509.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8348759/
Grim, T. W., Schmid, C. L., Stahl, E. L., et al. (2019). A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology, 45, 416–425.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6901606/
Herman, T. F., & Cascella, M. (2024). Mu receptors. StatPearls. National Library of Medicine.
https://www.ncbi.nlm.nih.gov/books/NBK551554/
Kudla, L., Przewlocki, R., & Mika, J. (2021). Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors. Pharmacological Reports, 73, 1033–1051.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8413226/
Kudla, L., Przewlocki, R., & Mika, J. (2022). Comparison of an addictive potential of μ-opioid receptor G protein-biased agonists, SR-14968 and SR-17018, and a reference compound, morphine. Pharmaceutics, 14(1), 55.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8779292/
Pantouli, F., Grim, T. W., Verpeut, J. L., et al. (2021). Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 in models of pain and tolerance. Neuropharmacology, 185, 108439.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7887086/
Pham, L., Ladner, A., Araujo, A., Blough, B. E., & Freeman, K. B. (2024). Characterizing biased mu-opioid receptor agonists, PZM21 and SR17018, in self-administration and whole-body plethysmography in rats. Drug and Alcohol Dependence, 260, 110021.
https://doi.org/10.1016/j.drugalcdep.2023.110021
Singleton, S., et al. (2024). Activation of μ receptors by SR-17018 through a distinctive mechanism. British Journal of Pharmacology.
https://pubmed.ncbi.nlm.nih.gov/39067665/
Stanczyk, M. A., Livingston, K. E., Chang, L., & Weinberg, Z. Y. (2018). Biased agonism: The quest for the analgesic holy grail. Pain Reports, 3(3), e650.
https://journals.lww.com/painrpts/fulltext/2018/06000/biased_agonism__the_quest_for_the_analgesic_holy.1.aspx
It’s easy and free!
John Ingham
John Ingham is a respected leader and medical content writer specializing in behavioral health, addiction treatment, and other mental health. With more than a decade of experience in the recovery and treatment field, his work has been featured across leading treatment networks and educational platforms, and has contributed as a lecturer in graduate level seminars within the Steve Hicks School of Social Work at University of Texas at Austin, and undergraduate seminars at Vanderbilt University. John's work has also been recognized in public service announcements, documentaries and more, including a feature that won an Emmy Award. John has collaborated with presidential appointees in the White House, clinicians, program directors, and other leaders throughout the behavioral health space, further establishing his role as a trusted voice in the field.
